Achaogen Announces Multiple Plazomicin Presentations at ASM Microbe 2017 Annual Meeting
(World News USA)

- Two oral presentations highlighting data from plazomicin Phase 3 EPIC and CARE clinical trials - - Eleven poster presentations highlighting plazomicin´s activity against MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE) - SOUTH SAN FRANCISCO, Calif., May 26, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multidrug-resistant (MDR) gram-negative infections, today announced 13 upcoming presentations on plazomicin at the American Society for Microbiology (ASM) Microbe 2017 Annual Meeting. The Company and its collaborators will deliver two oral presentations and 11 poster...